Piper Sandler Maintains Neutral on Core Laboratories, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Luke Lemoine maintains a Neutral rating on Core Laboratories (NYSE:CLB) and lowers the price target from $18 to $17.
July 15, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler analyst Luke Lemoine maintains a Neutral rating on Core Laboratories and lowers the price target from $18 to $17.
The lowered price target from $18 to $17 by Piper Sandler suggests a less optimistic outlook for Core Laboratories, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100